Finance

Beta
Lists
009290:KRX
Kwangdong Pharmaceutical Co Ltd
â‚©6,270.00
-2.49%
(-160.00) 1D
Jun 5, 3:30:23 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 009290...
Open
â‚©6,450
High
â‚©6,470
Low
â‚©6,230
Mkt. cap
312.24B
Avg. vol.
253.08K
Volume
145.72K
Dividend
1.59%
Quarterly dividend
â‚©25
Ex-dividend date
Mar 31, 2026
P/E ratio
12.10
52-wk high
â‚©12,800
52-wk low
â‚©5,500
EPS
â‚©518
Shares outstanding
49.80M
No. of employees
1K
Open
â‚©6,450
High
â‚©6,470
Low
â‚©6,230
Mkt. cap
312.24B
Avg. vol.
253.08K
Volume
145.72K
Dividend
1.59%
Quarterly dividend
â‚©25
Ex-dividend date
Mar 31, 2026
P/E ratio
12.10
52-wk high
â‚©12,800
52-wk low
â‚©5,500
EPS
â‚©518
Shares outstanding
49.80M
No. of employees
1K
News stories
From sources across the web
About Kwangdong Pharmaceutical Co Ltd
CEOSeong Won Choi
Employees1.02K
Founded1963
Headquarters-
SectorPharmaceutical industry
Websiteekdp.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
425.29B
444.52B
412.10B
410.85B
Cost of goods sold
353.25B
364.37B
331.32B
336.56B
Cost of revenue
353.25B
364.37B
331.32B
336.56B
Research and development expenses
1.78B
2.31B
2.52B
3.02B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
64.17B
64.25B
63.37B
59.62B
Operating expense
67.50B
69.28B
68.45B
66.77B
Total operating expenses
420.75B
433.65B
399.77B
403.33B
Operating income
4.54B
10.87B
12.33B
7.52B
Other non operating income
326.67M
163.53M
474.20M
-904.18M
EBT including unusual items
3.85B
14.32B
7.59B
6.56B
EBT excluding unusual items
-1.15B
10.58B
4.88B
8.31B
Income tax expense
1.46B
3.21B
3.82B
1.66B
Effective tax rate
37.79%
22.45%
50.37%
25.29%
Other operating expenses
215.14M
503.83M
440.15M
516.85M
Net income
2.51B
10.79B
3.93B
4.40B
Net profit margin
0.59%
2.43%
0.95%
1.07%
Earnings per share
-
-
-
-
Interest and investment income
880.10M
1.50B
1.31B
1.85B
Interest expense
-2.85B
-2.64B
-2.69B
-2.97B
Net interest expenses
-1.97B
-1.15B
-1.38B
-1.12B
Depreciation and amortization charges
1.67B
1.66B
1.75B
1.90B
EBITDA
9.17B
15.46B
17.02B
13.15B
Gain or loss from assets sale
91.02M
-517.21M
-156.85M
-77.73M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer